Abstract: The invention herein describes an improved and novel means of managing the complications of opioid analgesics, specifically treating the induction of emesis and itch by suppressing the activation of sensory afferent nerves. The composition of the botanical components that provides these benefits do not sacrifice hyperalgesia in order to negate the activity of sensory afferent nerves that drive emesis and itch, but in contrast affords significant analgesic actions in its own right. The combination of a therapeutic approach that negates an increased sensitivity to pain, itch, and nausea is a significant improvement over current treatment options.

Abstract: The invention herein describes a procedure for organically extracting the lipophilic components from plants of the Family Euphorbaciae, specifically but not limited to the genus Croton. The extraction (CGO 110), is deplete of the normal proanthocyanidin content found in the parent material, yet retains its pharmacocological abilities and unlike the parent material, is selectively cytotoxic to cancer cells. The depletion of the proanthocyanidin components makes the product more amenable to preparations for the benefit of ameliorating both human and animal disease.

Abstract: The method herein describes a process for the preparation and extraction of components from plants of the family Rubiaceae indigenous to South America, also known as Cat's Claw or Uña de gato. Cat's claw is an ethnomedicine that contains a variety of constituents, some of which have opposing actions. Oxindole and pentacyclic alkaloids have been proposed to be constituents that stimulate immune function, whereas polar constituents act to suppress immune response. An extract that was devoid of the aforementioned alkaloids would avoid opposing actions that may negate effectiveness or limit therapeutic outcome.

Abstract: An extract and procedure for extracting the polar components from plants of the Family Brassicaceae, specifically but not limited to the genus Lepidium. The extraction has an increased polar and decreased lipidic constituent concentration with an increased pharmacocological ability to affect growth parameters relative to the parent material. The concentration of polar constituents makes the product more amenable to preparations that increase growth parameters in aquaculture.

Abstract: An improved oral rehydration solution comprising standard formulae of sugars, mineral salts and bicarbonates in combination with Croton species materials with or without the inclusion of material from the Uncaria species. The botanical components are concentrated biologically active materials and thus enhance therapeutic benefit. The Croton component functions as an effective non-paralytic agent in managing diarrhea that is superior to loperamide resulting in a lower stool output. The functionality of the Uncaria species is as an effective anti-inflammatory agent via NF-□B activation inhibition and protecting gastrointestinal epithelial cells from oxidant-induced death.

Abstract: The invention herein describes a procedure for organically extracting the lipophilic components from plants of the Family Euphorbaciae, specifically but not limited to the genus Croton. The extraction (CGO 110), is deplete of the normal proanthocyanidin content found in the parent material, yet retains its pharmacocological abilities and unlike the parent material, is selectively cytotoxic to cancer cells. The depletion of the proanthocyanidin components makes the product more amenable to preparations for the benefit of ameliorating both human and animal disease.

Abstract: The method herein describes a process for the preparation and extraction of components from plants of the family Rubiaceae indigenous to South America, also known as Cat's Claw or U ña de gato. Cat's claw is an ethnomedicine that contains a variety of constituents, some of which have opposing actions. Oxindole and pentacyclic alkaloids have been proposed to be constituents that stimulate immune function, whereas polar constituents act to suppress immune response. An extract that was devoid of the aforementioned alkaloids would avoid opposing actions that may negate effectiveness or limit therapeutic outcome.

Abstract: The invention herein describes an improved and novel means of managing the complications of opioid analgesics, specifically treating the induction of emesis and itch by suppressing the activation of sensory afferent nerves. The composition of the botanical components that provides these benefits do not sacrifice hyperalgesia in order to negate the activity of sensory afferent nerves that drive emesis and itch, but in contrast affords significant analgesic actions in its own right. The combination of a therapeutic approach that negates an increased sensitivity to pain, itch, and nausea is a significant improvement over current treatment options.